Actavis Ltd v Merck & Co Inc (Costs) [2007] EWHC 1625 (Pat) (03 July 2007)

Actavis Ltd v Merck & Co Inc (Costs) [2007] EWHC 1625 (Pat) (03 July 2007)

The court held that while Actavis was the overall winner, the lack of overlap between the method of treatment and obviousness issues, and the significance of the obviousness issue, justified a partial costs order. Actavis was awarded 25% of its costs, and Merck was awarded 75% of 75% of its costs on the obviousness...

Source-derived case information.

Citation
[2007] EWHC 1625 (Pat)
Parties
Claimant: Actavis Limited; Defendant: Merck & Co. Inc.
Jurisdiction
England and Wales
Judgment Date
03 July 2007
Procedural Posture
Patent Costs Ruling / Post Trial, Costs Determination
Outcome
Costs apportioned: Actavis to recover 25% of its costs; Merck to recover 75% of 75% of its costs on the obviousness issue; net payment on account of £100,000 ordered to Merck; final amounts to be assessed or agreed.
Legal Topics
Patent Litigation, Costs Orders, Issue Based Costs, Obviousness, Amendment of Pleadings
Intellectual Property Civil Procedure Patent Litigation Costs Orders Issue Based Costs Obviousness Amendment of Pleadings

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 3 Authorities cited 10 Party arguments 2 Amounts and remedies 3
Sign in to unlock

Parties

Actavis Limited

Claimant

Merck & Co. Inc.

Defendant

Procedural Posture

Patent Costs Ruling / Post Trial, Costs Determination

  1. 1 How should costs be apportioned between the parties in a patent action where success is divided on different issues?
  2. 2 Is an issue-based costs order appropriate in this case?

Ratio Decidendi

The court held that while Actavis was the overall winner, the lack of overlap between the method of treatment and obviousness issues, and the significance of the obviousness issue, justified a partial costs order. Actavis was awarded 25% of its costs, and Merck was awarded 75% of 75% of its costs on the obviousness issue. The court declined to make a strict issue-based order, instead making a single overall order reflecting the divided success.

Court Disposition

Costs apportioned: Actavis to recover 25% of its costs; Merck to recover 75% of 75% of its costs on the obviousness issue; net payment on account of £100,000 ordered to Merck; final amounts to be assessed or agreed.

Orders

  • Actavis to recover 25% of its costs from Merck.
  • Merck to recover 75% of 75% of its costs on the obviousness issue from Actavis.